Related Experiment Video

Updated: Dec 21, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K

Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy

Christoph Mahler1, Michael Andrews1, Sian M Henson1

  • 1From the Department of Neurosciences (C.M., M.A., S.G.), the Royal London Hospital, Barts Health NHS Trust; and William Harvey Research Institute (S.M.H., S.G.), Barts & the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom.

Neurology(R) Neuroimmunology & Neuroinflammation
|May 22, 2020
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.4K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K